ISCT Open Access Webinars

Reprogramming hiPSC: Challenges getting stable lines and differentiating candidates for cell therapies 

01-06-2022 16:22


Reprogramming hiPSC and differentiation: Challenges in getting stable lines and good differentiating candidates for cell therapies explained. 

Produced by:

ISCT Asia Regional Executive Committee

Sponsored by:


Human iPSC derived cell therapies are surely progressing into medicine as evidenced by the clinical trials of neuroprogenitors for Parkinson’s disease, retinal epithelial (RPE) cells for Age related Macular Degeneration and cardiomyocytes for heart failure. Companies like Fate Therapeutics and Nekstar Therapeutics are also creating hiPSC to mass manufacture allogeneic immune cells for cancer therapies.

Yet, reprogramming and identifying high quality clones of hiPSC for cell and gene therapies that meets GMP requirements is very challenging. We will explore the techniques of selecting clones and testing for their ability to differentiate using different platforms such as embryoid bodies and microcarriers in order to identify the best conditions for lineages such as RPE, cardiomyocytes and haematopoietic stem cells. Examples of genetic aberrations and other rapid assays for screening hiPSC quality will be presented that will drive this field forward.

Learn about
  • What are the challenges to produce GMP iPSC lines?
  • What are the genetic abnormalities that are of concern?
  • What quality tests should be performed to check for genetic or functional abnormalities?
  • How to reprogramme hiPSC effectively with more candidates for screening?
  • What are the functional and differentiation assays to validate the quality of the cell lines?


1 Files

Related Entries and Links

No Related Resource entered.